<DOC>
	<DOCNO>NCT00448266</DOCNO>
	<brief_summary>This phase II/III trial investigate ability chemotherapy 'Intensified Aklylating Agents ( IAA ) achieve high pathological complete response ( pCR ) rate employ preoperative chemotherapy breast cancer evidence Homologous Recomination Deficiency ( HRD ) .</brief_summary>
	<brief_title>Intensified IAA With PBPC Support Breast Tumors With Evidence HRD</brief_title>
	<detailed_description>This phase II/III trial investigate ability chemotherapy 'Intensified Alkylating Agents ' ( IAA ) achieve high pathological complete response ( pCR ) rate employ preoperative chemotherapy breast cancer evidence Homologous Recombination Deficiency ( HRD ) . Homologous Recombination ( HR ) DNA repair mechanism repair double-strand DNA break . It reliable repair mechanism repair consequence DNA adduct cause bifunctional alkylating agensts ( cyclophosphamide , thiotepa carboplatin ) . Alternative DNA repair mechanism available case HRD , induce DNA mutation chromosome aberration thus give rise major genetic instability . HRD consequence inactivation BRCA-1 BRCA-2 , may also cause defect Fanconi anemia pathway amplification EMSY gene . HRD present breast cancer cell healthy cell BRCA-1 BRCA-2 mutation carrier , also 30 % sporadic breast cancer . Patients 60 year age intermediate high risk breast cancer , whose tumor show evidence HRD contain HER2/neu amplification eligible . All patient receive 3 course standard preoperative chemotherapy dose-dense Doxorubicin Cyclophosphamide ( ddAC ) . Patients favorable response accord repeat MRI , randomize undergo either 3 course ddAC prior local therapy endocrine adjuvant therapy ( standard arm ) 1 course ddAC follow peripheral blood progenitor cell ( PBPC ) harvest 2 course IAA Cyclophosphamide ( 3 g/m2 ) , thiotepa ( 240 mg/m2 ) carboplatin ( 800 mg/m2 ) ( experimental arm ) . IAA administer 1 2-night hospital stay , bone marrow aplasia phase manage out-patient basis second course start day 22 first one . Patients achieve favorable response determine MRI 3 cycle ddAC offer treatment accord experimental arm salvage therapy . The primary endpoint study pCR rate breast . The phase II part study serve develop pathology test HRD estimate pCR rate HRD-breast cancer conventional experimental treatment . The phase III part study initiate test HRD sufficiently standardize employed multi-center set preliminary information collect point continue consistent assumption HRD render tumor cell highly sensitive IAA . If breast cancer indeed exquisitely sensitive IAA , pCR rate experimental arm could rise 10 % 30 % luminal tumor type 50 % 80 % basal-like tumor type . For 80 % power detect response-improvement , 186 patient HRD must include phase III part study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<criteria>Proven infiltrate breast cancer either primary tumor 3 cm size ( clinical examination ) cytologically prove spread axillary lymph node . Stage II stage III disease ( revise AJCC stag system 2001 ) . Patients 'locally advance breast cancer ' consequently eligible , include ipsilateral supraclavicular lymph node metastasis . In stage II patient T1N1 disease , N1 status must demonstrate either fine needle aspiration axillary lymph node metastasis 2 mm diameter sentinel node biopsy . Stage IIA patient without lymph node metastasis eligible tumor 3 cm diameter . Highrisk disease , accord Adjuvant Online version 8.0 : expect 10year recurrencefree survival without systemic adjuvant therapy accord program must 60 % low . The tumor must HER2/neunegative ( either score 0 1 immunohistochemistry negative situ hybridization [ CISH FISH ] case score 2 3 immunohistochemistry ) . The tumor must test positive homologous recombination deficiency , define test pathology department NKIAVL ( M.J. van de Vijver ) . Age 18 59 year ; patient older 59 year may include consider 'biologically 59 year young ' . Performance status : WHO 0 I . No previous radiation therapy chemotherapy . No malignancy except carcinoma situ , unless malignancy treat 5 year ago curative intent without use chemotherapy radiation therapy . Adequate bone marrow function ( W.B.C . count &gt; 3.0 x 109/l , platelet &gt; 100 x 109/l ) . Adequate hepatic function ( ALAT , ASAT bilirubin &lt; 2 x upper limit normal ) . Adequate renal function ( creatinine clearance &gt; 60 ml/min ) . Radionuclide ejection fraction &gt; 0.50 . Pregnancy breast feed must exclude patient must use adequate contraceptive protection . No evidence distant metastasis . Staging examination must include chest roentgenogram , ultrasound examination liver isotope bone scan . Abnormal uptake isotope bone scan accept bone metastasis exclude MRI . At randomization , hormone receptor status HER2/neu receptor status must know . In case 2+ HER2/neu expression immunohistochemistry , FISH CISH examination require . Informed consent .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>high-dose chemotherapy</keyword>
	<keyword>Homologous Recombination Deficiency</keyword>
	<keyword>Alkylator therapy</keyword>
	<keyword>Peripheral Blood Progenitor Cell Support</keyword>
</DOC>